CliffBio
small molecule

STEGLATRO

ERTUGLIFLOZIN

Loss of exclusivityDecember 2031latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Drug detail

Brand nameSTEGLATRO
Active ingredientERTUGLIFLOZIN
Strength15MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2017
Marketing statusRX

Listed patents

PatentExpiresType
8080580December 2031substance, product

More from MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

STEGLATRO patent cliff — loss of exclusivity December 2031 | CliffBio